StreetInsider.com News Articles

Form 8-K Kairos Pharma, LTD. For: Jul 15

Wed, 15 Jul 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260715/26771484.html

Form 8-K Kairos Pharma, LTD. For: Jul 15

Wed, 15 Jul 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260715/26771484.html

Form 8-K Kairos Pharma, LTD. For: Jun 29

Tue, 30 Jun 2026 17:19:00 -0400

si-local-file:///var/storage/secattach/20260630/26714861.html

Form 8-K Kairos Pharma, LTD. For: Jun 29

Tue, 30 Jun 2026 17:19:00 -0400

si-local-file:///var/storage/secattach/20260630/26714861.html

Kairos Pharma signs term sheet to acquire cancer drug CL-741

Thu, 04 Jun 2026 08:01:08 -0400

Kairos Pharma Ltd. (NYSE American: KAPA) announced it signed a term sheet to acquire worldwide rights to CL-741, a clinical-stage oncology asset from privately held Celyn Therapeutics Inc.

CL-741 is described as a Phase 1-ready, orally available type IIb c-MET kinase inhibitor targeting non-small cell lung cancer and esophageal and gastric cancer. The drug specifically targets EGFR-mutated lung cancer, according to the company's shareholder letter.

Celyn Therapeutics is backed by OrbiMed and Torrey Pines Investment. The acquisition would add CL-741 to Kairos Pharma's existing pipeline, which includes ENV-105, KROS-201, KROS-102 and ENV-205.

Kairos Pharma outlined several planned milestones for the remainder of 2026,

Kairos Pharma signs term sheet to acquire cancer drug CL-741

Thu, 04 Jun 2026 08:01:08 -0400

Kairos Pharma Ltd. (NYSE American: KAPA) announced it signed a term sheet to acquire worldwide rights to CL-741, a clinical-stage oncology asset from privately held Celyn Therapeutics Inc.

Celyn Therapeutics is backed by OrbiMed and Torrey Pines Investment. The acquisition would add CL-741 to Kairos Pharma's existing pipeline, which includes ENV-105, KROS-201, KROS-102 and ENV-205.

Kairos Pharma outlined several planned milestones for the remainder of 2026,

Form 8-K Kairos Pharma, LTD. For: Jun 04

Thu, 04 Jun 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260604/26602738.html

Form 8-K Kairos Pharma, LTD. For: Jun 04

Thu, 04 Jun 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260604/26602738.html

Kairos Pharma Recaps Important Acquisitions and Details Plans for the Balance of 2026 in Letter to Shareholders

Thu, 04 Jun 2026 08:00:00 -0400

LOS ANGELES--(BUSINESS WIRE)-- Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, provides a mid-year update for 2026 and a look ahead to the rest of the year in a letter to shareholders from CEO John Yu, M.D.: